Enliven Therapeutics, Inc.
ELVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. With a market capitalization of $4.35B, it sits in mid-cap territory. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Market Cap
$4.35B
Beta
0.24
P/E (TTM)
—
P/E (Fwd)
-25.37
EPS (TTM)
$-1.65
EPS (Fwd)
$-2.34
ROE
-15.3%
ROA
-11.0%
Cash
$895.2M
Total Debt
$1.5M
Free CF
-$45.3M
52W Change
200.8%
Annual Financials
Cash vs Debt
Where ELVN stands vs its 150-day and 200-day moving averages
As of the August 19, 2026 close, ELVN finished 49.06% above its 150-day moving average ($40.30) and 71.19% above its 200-day moving average ($35.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELVN overbought or oversold?
At the August 19, 2026 close, ELVN's RSI(14) was 73.7, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Enliven Therapeutics, Inc. holds $895.2M in cash against $1.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$45.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -15.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
ELVN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ELVN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Enliven Therapeutics, Inc. and its sector.